Xilio Therapeutics, Inc.’s Post

Start ups are starting-up all over the United States in Cannabis & in #Psychedelic medicine. But are they “highly capitalized 💰?” Most aren’t, but if you want to reach investors at scale DM me & ask about the performance of sponsored content using Highly Capitalized. ✅ Thanks to our #proven ‘marketing funnel’ (& a bit of good luck) 🍀 —you’ll find that #strategic investor (or investors) you always wanted. ⭐️ We also work with the main Broker Dealers in New York & San Francisco on Reg A, Reg D and Reg CF #capital raises. Feel free to ask about other ways of raising capital including #debt. 👍 We’ve also succeeded in helping public companies to promote their IPO or #RTO. ☑️ We’re licensed & insured to do what we do —to help companies reach investors at #scale using our #proprietary methodologies. 🎸 Come on board to Highly Capitalized as a sponsor, sit back and let us generate leads at scale for you—of investors #active in #Cannabis

📢 Industry Deals Update Platinum Equity is set to buy Héroux-Devtek in a $1.35 billion deal, reflecting the strong interest in the aerospace sector, driven by ongoing advancements and demand. New Harbor Capital-backed AIC acquires Big Sky, a home and specialty infusion services provider. The acquisition aligns with the growing trend towards home-based healthcare solutions, driven by patient convenience and cost-efficiency. Osceola Capital-backed Revelation Pharma acquires Taylor's Pharmacy and Key Compounding Pharmacy - Underscoring the importance of specialty pharmacies in providing customized medication solutions, which are becoming increasingly vital in personalized medicine. The Carlyle Group's recent acquisition of the Seattle Reign highlights the increasing investment potential in women's sports as viewership and fan engagement continue to rise. #PrivateEquity #TechDeals #IndustryNews #Acquisitions #Aerospace #WomenInSports #Healthcare

In a Q4 with a subdued start for private healthcare markets, Aiolos Bio, a clinical-stage biotech, made waves with a massive $245M Series A round. Learn more in our most recent Market Healthcare Update: https://bit.ly/468ziul

Delve into 'Which Is a Better Investment, AbbVie Inc or HALEON PLC - ADR Stock?' for a comparative analysis. With A+ Investor, explore key metrics like Value, Quality, and Estimate Revisions to make informed investment decisions. #Investing READ: https://ow.ly/pcnE50QK4hr

Hutchison continues to demonstrate its leadership in the U.S. and the Southeast among top venture law firms with the following rankings in PitchBook Q2 2023 Global League Tables: https://ow.ly/wEzM50PC793 #19 Most Active in Software #12 Most Active in Pharma & Biotech #16 Most Active in US: Investors #21 Most Active in US Companies #5 Most Active in the Southeast #21 Most Active in the Mid-Atlantic #22 Most Active in the West Coast #19 Most Active in the US #23 Most Active in Late Stage

Are you planning to take your life sciences company public? This is a big move, one that demands intensive planning and preparation. You need to perform all the usual due diligence of a standard IPO, combined with extra oversight to make sure you're meeting all the regulatory requirements for your field. In our guide, we lay out everything you need to know, step by step. Check it out and make sure you're prepared: https://bit.ly/4bC199Q #CFGI #LifeSciences #IPO #GoingPublic

Novo Holdings A/S Acquires Majority Stake in Single Use Support Novo Holdings will acquire an approximately 60% controlling stake, alongside the two company founders who will each retain 10% and Danaher which will retain 20% of the share capital. Johan Hueffer, Senior Partner, Principal Investments, Novo Holdings, said: “We are pleased to announce the acquisition of a majority stake in Single Use Support, a leading provider of advanced fluid management solutions. This transaction marks an important and complimentary addition to our fast-growing life science tools & diagnostics portfolio and represents our first control investment in the DACH region, a vital hub for life sciences. This investment also underscores our commitment to advancing leading healthcare therapies and technologies.” The financial details of the deal have not been officially disclosed but Reuters reported that the transaction implied a "high triple-digit million euros" amount. https://lnkd.in/dDSEbZHr #aspenalert #biotech #bioprocess

Is the healthcare IPO dry spell coming to an end? 🎥 The short video below provides a sneak peek of the full interview. Vincent Meunier, Healthcare Managing Director at Bryan Garnier, sat down with Grégoire Favet on BSMART to discuss the current state of capital transactions, IPOs, and M&A activity in the European healthcare sector, as well as market commentary on AstraZeneca and Amolyt Pharma. As a full-service investment bank, Bryan Garnier is uniquely positioned to share insights on both IPO and M&A dynamics and provide tailored strategic advisory services to European growth companies. #IPOs #ECM #Healthcare #IndustryInsights #SmartBourse #BryanGarnier Watch a “best of” of the video with English subtitles below and stay tuned for the full interview! 👇

Delve into 'Which Is a Better Investment, AbbVie Inc or HALEON PLC - ADR Stock?' for a comparative analysis. With A+ Investor, explore key metrics like Value, Quality, and Estimate Revisions to make informed investment decisions. #Investing READ: https://ow.ly/pcnE50QK4hr

Roche Finance Europe issued EUR 1.5 billion bonds guaranteed by Roche Holding, advised by Homburger. Advestra advised BNP Paribas and the banking syndicate on the placement. Banco Santander, BNP Paribas and UniCredit Bank acted as joint lead managers. The bonds will be listed on the SIX Swiss Exchange and have been admitted to trading on the Open Market (Freiverkehr) of the Frankfurt Stock Exchange. The first tranche was issued in the aggreg­ate prin­cip­al amount of EUR 650,000,000, has a coupon of 3.227% and is due in 2030. The aggreg­ate prin­cip­al amount of the second tranche amounts to EUR 850,000,000, has a coupon of 3.564% with a matur­ity date in 2044. The documentation is governed by Swiss law. Homburger acted as an advisor for Roche Holding with a team led by financing and investment products partner Jürg Frick (pictured left), which also comprised Eduard De Zordi and Daniel Hulmann (both capital markets). Advestra acted as Swiss leg­al coun­sel to the man­agers, with a team led by partner Annette Weber (pictured right) and including Valérie Bayard (all cap­it­al mar­kets) as well as Céline Mar­tin (tax). Read the article >> https://lnkd.in/dz3ZjNyS #Legalcommunitych #legaladvisor #bonds #issuance